✦ LIBER ✦

Considerations for early switch to nilotinib or dasatinib in patients with chronic myeloid leukemia with inadequate response to first-line imatinib

✍ Scribed by Quintás-Cardama, Alfonso; Jabbour, Elias J.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cost-Utility Analysis of Dasatinib and N

✍ Kulpeng, Wantanee; Sompitak, Sumalai; Jootar, Saengsuree; Chansung, Kanchana; Te 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 433 KB

Dasatinib early intervention after cytog

✍ Alfonso Quintás-Cardama; Jorge E. Cortes; Susan O'Brien; Farhad Ravandi; Gautam 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 182 KB 👁 2 views

Adherence to treatment with second-line

✍ Yood, Marianne Ulcickas; Oliveria, Susan A.; Cziraky, Mark; Hirji, Ishan; Hamdan 📂 Article 📅 2012 🏛 Informa plc 🌐 English ⚖ 206 KB

Second-Line Therapy for Patients With Ch

✍ Lau, Anna; Seiter, Karen 📂 Article 📅 2014 🏛 Elsevier 🌐 English ⚖ 337 KB

Comparing nilotinib with dasatinib as se

✍ Griffin, James D.; Guerin, Annie; Chen, Lei; Macalalad, Alexander R.; Luo, Jiayu 📂 Article 📅 2013 🏛 Informa plc 🌐 English ⚖ 305 KB

Molecular response to first line nilotin

✍ Stephen E. Langabeer; Sarah L. McCarron; Peig Carroll; Johanna Kelly; Michael O’ 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 138 KB